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Historically, coronaviruses were predominantly associated with mild upper respiratory disease in humans.
More recently, three novel coronaviruses associated with severe human respiratory disease were found,
including (i) the severe acute respiratory syndrome coronavirus, associated with a significant atypical pneu-
monia and 10% mortality; (ii) HKU-1, associated with chronic pulmonary disease; and (iii) NL63, associated
with both upper and lower respiratory tract disease in children and adults worldwide. These discoveries
establish coronaviruses as important human pathogens and underscore the need for continued research
toward the development of platforms that will enable genetic manipulation of the viral genome, allowing for
rapid and rational development and testing of candidate vaccines, vaccine vectors, and therapeutics. In this
report, we describe a reverse genetics system for NL63, whereby five contiguous cDNAs that span the entire
genome were used to generate a full-length cDNA. Recombinant NL63 viruses which contained the expected
marker mutations replicated as efficiently as the wild-type NL63 virus. In addition, we engineered the heter-
ologous green fluorescent protein gene in place of open reading frame 3 (ORF3) of the NL63 clone, simulta-
neously creating a unique marker for NL63 infection and demonstrating that the ORF3 protein product is
nonessential for the replication of NL63 in cell culture. The availability of the NL63 and NL63gfp clones and
recombinant viruses provides powerful tools that will help advance our understanding of this important human
pathogen.
Coronaviruses (CoVs) are the largest known single-stranded
positive-sense RNA viruses; they encode 5-capped, polyade-
nylated genomes ranging in size from 27 to 32 kb. Until re-
cently, CoVs were predominantly associated with severe dis-
ease in domestic animals, including bovines (bovine CoV),
swine (porcine epidemic diarrhea virus and transmissible gas-
troenteritis virus [TGEV]), avians (infectious bronchitis virus
[IBV]) (2, 8, 30, 36), and mice (mouse hepatitis virus [MHV])
(42), while infections in humans were primarily associated with
mild upper respiratory tract diseases caused by human CoVs
(hCoVs) hCoV-229E and hCoV-OC43 (30). However, the
identification of a novel CoV as the etiological agent respon-
sible for severe acute respiratory syndrome (SARS), an atyp-
ical pneumonia with a 10% mortality rate (53), indicated that
hCoVs are capable of causing severe disease in humans and
that unidentified hCoVs continue to exist in nature. More-
recent discoveries have led to the identification of two addi-
tional hCoVs: (i) HKU-1, which has been associated with
chronic pulmonary disease in humans (32), and (ii) NL63,
which has been associated with both upper and lower respira-
tory tract disease in children and adults worldwide (1, 5, 9–11,
13, 23, 27, 28, 57, 62, 63). In addition, NL63 has been associ-
ated with croup in infants and young children (45, 60, 61).
Croup is a disease caused by many different viruses which is
characterized by the sudden onset of a distinctive barky cough,
stridor, hoarse voice, and respiratory distress resulting from
upper-airway obstruction (6). Croup accounts for roughly
250,000 hospitalizations each year in the United States, and
cases severe enough to require hospitalization can be fatal
(24). In addition, although understudied, hCoV infection can
result in a particularly severe pneumonia in the elderly, as
evidenced by an outbreak of hCoV-OC43 in a retirement com-
munity that was associated with an 10% mortality rate (41).
Taxonomically, CoVs are classified as members of the order
Nidovirales, family Coronaviridae, genus Coronavirus (14, 30,
37). Currently, the Coronavirus genus is further divided into
three primary groups based upon serological and phylogenetic
data. Among the hCoVs, group 1 contains NL63 and hCoV-
229E, while group 2 strains include hCoV-OC43, HKU-1, and
SARS-CoV (14). The CoVs are roughly 100 nm in diameter,
are enveloped, and contain three core structural spikes, includ-
ing a 180- to 190-kDa spike glycoprotein (S), a 26-kDa mem-
brane glycoprotein (M), and an envelope protein (E) of 9
kDa. The genomic RNA is surrounded by a helical nucleocap-
sid composed of the 50- to 60-kDa nucleocapsid protein (N)
(46).
Interestingly, despite large differences in S glycoprotein se-
quences (less than 50% identity at the nucleotide level) be-
tween SARS-CoV and NL63, both viral S glycoproteins have
been reported to interact with human angiotensin-converting
enzyme-2 (ACE2) as a receptor for docking and entry into cells
(25, 34, 44, 52). Upon entry into the host cell, the genomic
RNA is uncoated and immediately translated into two large
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polyproteins (30, 36). The first two-thirds of the CoV genome
encodes nonstructural replicase proteins in two overlapping
open reading frames (ORFs). The final one-third of the ge-
nome consists of the structural proteins S, E, M, and N, as well
as accessory proteins specific to different strains which are
translated from a nested set of 3 coterminal subgenomic
mRNAs (30, 36). For NL63, there are six genes with a gene
order of 5-replicase-S-ORF3-E-M-N-3, wherein gene 1 en-
codes the nonstructural replicase proteins, gene 2 encodes S,
gene 3 encodes an accessory protein of unknown function
known as ORF3, gene 4 encodes E, gene 5 encodes M, gene 6
encodes N, and an overlapping ORF6b has been predicted to
encode an additional accessory protein of unknown function
(47, 59). All CoV genomes contain group-specific genes in the
final one-third of the genome, and many of these genes encode
group-specific accessory proteins of undetermined function
that are dispensable for replication (17, 68). Interestingly,
ORF3 of NL63 encodes a 225-amino-acid protein that is ho-
mologous to ORF4 of hCoV-229E (53% similarity) and to
ORF3A of SARS-CoV (23% similarity) (39), and both of these
proteins have unknown functions.
Full-length cDNA constructs of CoV genomes have revolu-
tionized reverse genetic applications in coronavirology (7, 66–
68). The strategy employed by our laboratory has been to
divide the genome into stable cDNA fragments flanked by
native or engineered type IIS restriction endonuclease sites
that form unique junctions at the ends of each fragment. In
addition, a T7 promoter site is added to the first fragment (at
the 5 end of the genome) to enable in vitro transcription of the
full-length cDNA fragment after ligation, and a poly(A) tail is
included at the end of the last fragment (at the 3 end). For
assembly, the fragments are cleaved by restriction digestion,
which removes the nonnative portion of the restriction site and
sequence, leaving unique ends that allow for a seamless, uni-
directional ligation of the full-length cDNA clone. Transcrip-
tion of the full-length cDNA is driven by the T7 promoter, and
the full-length infectious RNA is transfected into cells. The
individual fragments can be easily stored and amplified, and
the smaller cDNA sizes are more manageable for targeted
mutagenesis studies. This infectious clone strategy has been
successfully employed for TGEV (65), MHV strain A59 (67),
hCoV SARS-CoV strain Urbani (66), and IBV (64).
In this study, we report and characterize the first full-length
infectious clone of NL63 (icNL63). In addition, we replaced
ORF3, which encodes a protein of unknown function, with the
heterologous green fluorescent protein gene (GFP), simulta-
neously developing a new marker for NL63 infection and dem-
onstrating that the protein product of ORF3 is nonessential for
efficient viral replication in LLC-MK2 cells and primary cul-
tures of human ciliated airway epithelium (HAE).
MATERIALS AND METHODS
Virus and cells. The NL63 virus and LLC-MK2 cells were generously provided
by Lia van der Hoek. The LLC-MK2 cell line is an epithelial line established in
the 1950s from a pooled suspension prepared from kidney tissue of six adult
rhesus monkeys (Macaca mulatta) (26). The LLC-MK2 cells were maintained at
37°C with 5% CO2 in minimal essential medium supplemented with 10% fetal
clone II (Gibco), 10% tryptose phosphate broth, and gentamicin (0.05 g/ml)–
kanamycin (0.25 g/ml). NL63 was propagated on these cells, and the infections
were maintained at 32°C in incubators maintained at 5% CO2.
Human nasal and tracheobronchial epithelial cells were obtained from airway
specimens resected from patients undergoing elective surgery under UNC Insti-
tutional Review Board-approved protocols by the UNC Cystic Fibrosis Center
Tissue Culture Core. Briefly, primary cells were expanded on plastic to generate
passage 1 cells and plated at a density of 250,000 cells per well on permeable
Transwell-Col (12-mm diameter) supports (18, 43). HAE cultures were gener-
ated by the provision of an air-liquid interface for 4 to 6 weeks to form well-
differentiated, polarized cultures that resemble in vivo pseudostratified ciliated
epithelium (43).
Design of the icNL63 and icNL63gfp clones. Initial attempts at generating a
synthetic NL63 clone based upon the genomic NL63 sequence originally depos-
ited in GenBank in June 2004 with accession number NC_005831 were unsuc-
cessful. However, this sequence was later updated with several corrections
(NC_005831.2); these corrections were engineered into the synthetic clone, but
we were still unable to successfully rescue recombinant virus. We then acquired
the virus (as a kind gift from Lia van der Hoek), sequenced it, and attempted to
generate the clone from this sequence, but yet again were unsuccessful at res-
cuing recombinant virus. This viral sequence was different from NC_005831.2 at six
positions, and this viral stock was later determined to be problematic. A second
shipment of virus was requested and used to successfully generate the clone de-
scribed here (FJ211861). It is important to note that the NL63 genome is AT rich
(66%), which likely contributed to problems with cloning and sequencing.
Once a reliable virus sample and sequence were established, icNL63 was
amplified from viral cDNA (FJ211861) and cloned as a set of five fragments
(Table 1). The first fragment, NL63-A, was PCR amplified using primer set
5T7NL63 (5-GGTACCTAATACGACTCACTATAGCTTAAAGAATTT
TTCTATCTATAG-3) and NL63:A (5-GCGGCCGCGTCTCCAGGAGC
TGTGGGTTGAACAG-3). These primers created a T7 RNA promoter at
the 5 end of the fragment and a BsmBI restriction site at the 3 end,
respectively. The PCR product was gel isolated and then cloned into the
pCR-XL TOPO cloning vector (Invitrogen). The second fragment, NL63-B,
was amplified using primers NL63:B (5-GCGGCCGCGTCTCCTCCTGC
ATATGTTATTATTGATAAG-3) and NL63:B (5-GCGGCCGCGTCTC
TGCTGGGGAAGAAGCTATTATCAAG-3). Fragment NL63-C was am-
plified with primers NL63:C (5-GCGGCCGCGTCTCCCAGCACTCGTT
GATCAACGCAC-3) and NL63:C (5-GCGGCCGCGTCTCTCTTTAGA
GACATTTTCACCATC-3). Both of these fragments, which are flanked with
TABLE 1. Primers used to generate infectious clone fragments
and for PCR
Primer Nucleotide position Comment
5T7NL63 5 end of genome Creates 5 T7 RNA
polymerase promoter
NL63:A 6907–6928 Creates BsmBI junction
between A and B
NL63:B 6922–6948 Creates BsmBI junction
between A and B
NL63:B 13537–13562 Creates BsmBI junction
between B and C
NL63:C 13556–13579 Creates BsmBI junction
between B and C
NL63:C 19988–20011 Creates BsmBI junction
between C and D
NL63:D 19991–20014 Creates BsmBI junction
between D and D
NL63:D 23845–23875 Creates BstAPI junction
between D and E
NL63:E 23854–23882 Creates BstAPI junction
between D and E
NL63:E 3 end of genome Creates 3 poly(A) tail at
end of genome
NL63-N1s Leader sequence Real-time PCR primer
NL63-N1a 69–47 antisense of N Real-time PCR primer
for 116-nt amplicon
NL63-NR 255–236 antisense of N RT-PCR primer (with
NL63-N1s) for 302-nt
amplicon
NL63-73002 23582–23599 genomic 350 nt 5 of BstAPI site
NL63-7R 24490–24471 antisense
genomic
650 nt 3 of BstAPI site
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BsmBI sites, were gel isolated and cloned into the Big Easy v2.0 linear cloning
vector (Lucigen). Fragment NL63-D was amplified using primer NL63:D
(5-GGTGAAAACGTCTCTAAAGATGG-3) and primer NL63:D (5-CA
GCAGCACAGTATGCAGAAAAAGCAAACC-3). This primer set created
a BsmBI site at the 5 end and a BstAPI restriction site at the 3 end. The last
fragment, NL63-E, was PCR amplified using primers NL63:E (5-TTTCT
GCATACTGTGCTGCTGCCAACTG-3) and NL63: E (5-TTTTTTTTT
TTTTTTTTTTTTTTTGTGTATCCATATCAAAAACAATATCATTAACA
AGTACC-3) and contained a BstAPI site at its 5 end. The BstAPI site at
the NL63-D and NL63-E junction was engineered by silent mutagenesis into
the genomic sequence such that it would be retained after ligation of the two
fragments, providing a unique marker for confirming that recombinant vi-
ruses were derived from the cloned cDNA. The last two fragments, NL63-D
and NL63-E, were gel purified and subsequently cloned into the pCR-XL
TOPO vector. The 5 approximately 630 bp of the NL63-E fragment was PCR
amplified using the primer set NL63:E and Ngfp2 (5-CCATTATTGAA
CGTGGACCTTTTC-3). The gene encoding GFP was amplified with primer
Ngfp1 (5-GAAAAGGTCCACGTTCAATAATGGTGAGCAAGGGCGA
GG-3) and primer Ngfp3 (5-GGTCACCTTACTTGTACAGCTCGTCCA
TG-3). These two amplicons were joined in an overlapping extension PCR,
and the resulting product was cloned into the pCR-XL cloning vector. A
consensus clone was generated by using standard recombinant DNA tech-
niques, and the BstAPI to BstEII fragment from this clone was inserted into
the NL63-E fragment, which had also been digested with BstAPI and BstEII.
The resulting plasmid then contained gfp in place of the NL63 ORF3, and this
fragment was designated NL63-Egfp (Fig. 1).
Systematic assembly of full-length NL63 cDNAs for icNL63 and icNL63gfp.
For assembling the infectious clones, plasmids incorporating cDNA fragments
NL63-A through NL63-E were transformed into chemically competent Top 10
cells (Invitrogen) by heat shock at 42°C for 2 min and then plated on Luria
Bertani (LB) plates with appropriate selection (kanamycin [25 g/ml] or chlor-
amphenicol [20 g/ml]). Colonies were picked and grown under appropriate
selection conditions in 5 ml of LB broth maintained at 28.5°C for 16 to 24 h and
then purified and screened by restriction digestion. Larger 20-ml stocks were
grown at 28.5°C for 24 h to 48 h for each of the cDNAs. Purified plasmids were
then digested as follows: NL63-A, NL63-B, and NL63-C were digested with
BsmBI, and NL63-D and NL63-E were digested under the appropriate condi-
tions with BsmBI and BstAPI. NL63-Egfp was digested with BstAPI and BsmBI.
Of note, the fragment boundaries were established by trial and error, as toxic
regions in the genome prevented the cloning of several preliminary fragments.
After digestion, fragments were electroporated on 0.8% (wt/vol) agarose gel,
and appropriate bands were excised and gel purified by using a Qiaex II gel
extraction kit (Qiagen) with modifications (67). Briefly, all fragments were re-
suspended in 620 l of QXI buffer, 11 l Qiaex II silica gel particles, and 12.5 l
3 M sodium acetate and eluted in 35 l of elution buffer heated to 70°C. Purified
fragments NL63-A through NL63-E were ligated by using T4 DNA ligase (Pro-
mega) overnight at 4°C in a total reaction mixture volume of200 l to generate
the wild-type (wt) icNL63. For the NL63 clone expressing GFP (icNL63gfp), the
NL63-Egfp fragment was used instead of the NL63-E fragment.
Transfection of full-length transcripts. The full-length cDNAs were then
further purified by chloroform extraction and isopropanol precipitation, tran-
scribed using a T7 transcription kit (Ambion/Applied Biosystems), cotransfected
into 8  106 LLC-MK2 cells in parallel with the N gene driven by an SP6
promoter, and transcribed with an SP6 transcription kit (Ambion/Applied Bio-
systems). LLC-MK2 cells were efficiently transfected with one pulse at 200 V and
950 ferrads using a Bio-Rad (Hercules, CA) Gene Pulser Xcell electroporator.
Electroporated LLC-MK2s were plated in T25 flasks and incubated at 32°C for
up to 7 days.
Detection of recombinant NL63 and NL63gfp replication. To determine if
replication occurred in the icNL63-transfected cultures, cells were examined at
regular intervals for cytopathic effect (CPE). However, CPE was not definitive at
7 days posttransfection, so half of the cells and supernatants were passaged with
fresh cells and media, and cultures observed for an additional 7 days, prior to a
third passage. At each passage, infected cells were harvested in Trizol reagent,
total RNA was isolated, and reverse transcriptase PCR (RT-PCR) targeting
subgenomic RNA was conducted using primers specific to the leader sequence
and the 5 end of the N gene (Table 1). Briefly, viral RNA was reverse tran-
scribed to cDNA by using SuperScript III (Invitrogen) with modification to the
protocol as follows. Random hexamers (300 ng) and total RNA (5 g) were
incubated for 10 min at 70°C. The remaining reagents were then added according
to the manufacturer’s recommendation, and the reaction mixture was incubated
at 55°C for 1 h followed by 20 min at 70°C to deactivate the RT. For RT-PCR,
a forward primer in the leader sequence (NL63-N1s, GATAGAGAATTTTCT
TATTTAGACTTTGTG) and a reverse primer250 nucleotides (nt) into the N
gene (NL63-NR, AGGTCCAGTACCTAGGTAAT) were used to generate a
302-bp product by PCR (Table 1).
Real-time RT-PCR was also conducted with the same cDNA templates by
using a SmartCycler II (Cepheid) with Sybr green (diluted to 0.25; Cepheid) to
detect subgenomic cDNA with primers (7.5 pM) optimized to detect 116 nt
spanning from the leader sequence (NL63-N1s; GATAGAGAATTTTCTTAT
TTAGACTTTGTG) to the 5 end of the N gene (NL63-N1a; CATGTAAAAT
GAAGGAGGAGGAA) (Table 1). The cDNA from the RT reaction of each
virus was used at a volume of 2 l for each reaction mixture, with a total reaction
mixture volume of 25 l. Omnimix beads (Cepheid) containing all reagents
except Sybr green, primers, and template were used to standardize the reaction
conditions. In addition, all products were verified by melting curve analysis.
For icNL63gfp, replication was confirmed by observing GFP fluorescence.
Infections were passaged as described above until nearly 100% of cells were GFP
positive, at which time the supernatants and cells were harvested. Replication
was further verified by RT-PCR, using primers specific to subgenomic N tran-
scripts.
Plaque purification and titration of rescued virus. Supernatants harvested
from passage 3 of the transfections were diluted 1:10, and 200 l of dilutions
from 100 to 105 were poured onto LLC-MK2 cells in six-well plates. After a 1-h
adsorption period, 5 ml of overlay (0.8% [wt/vol] LE agar [Lonza, Inc.], 10% fetal
clone II, 40% 2 minimal essential medium, 1% gentamicin-kanamycin) was
added to each culture, and the infections were maintained at 32°C for 7 days. To
help visualize the plaques, the plates were stained with neutral red for 1 h at
32°C, and five plaques were picked for each virus. Each plaque was incubated in
phosphate-buffered saline (PBS) at 32°C for 30 min and then poured onto fresh
LLC-MK2 cells and grown at 32°C for up to 9 days to allow for the propagation
of purified virus. For the NL63gfp recombinant virus, plaques were clearly visible
by fluorescent microscopy, and five plaques were picked and propagated as
described above. The titers for both recombinant icNL63 and recombinant
icNL63gfp were determined by plaque assay using LLC-MK2 cells. Briefly, LLC-
MK2 cells were infected in duplicate with 200 ls of each serial dilution of 100
to 105 of recombinant icNL63 or recombinant icNL63gfp in six-well plates with
a 1-h adsorption period. Five milliliters of overlay (0.8% [wt/vol] LE agar [Lonza,
Inc.], 10% fetal clone II, 40% 2 minimal essential medium, 1% gentamicin-
kanamycin) was added to each infection, and the plates were maintained at 32°C
until plaques were observed (between 4 and 7 days). To visualize plaques, plates
were stained with neutral red for 2 h at 32°C and then incubated overnight prior
to counting.
Detection of marker mutations. A unique BstAPI restriction endonuclease site
was engineered into both the icNL63 and icNL63gfp clone to facilitate the
unidirectional ligation of the NL63-D and NL63-E fragments. This engineering
introduced a unique but silent BstAPI restriction endonuclease site from posi-
tion 23916 to 23925 of both clones. This site was used to verify that the plaque-
purified viruses harvested originated from the infectious clones. Primers flanking
FIG. 1. The gene order of NL63 and the strategies used to generate
the infectious clones. (A) The NL63 genome contains six genes, with
ORF1a and -b encoding the viral nonstructural proteins involved pri-
marily in replication. Genes 2 to 6 encode the structural and accessory
proteins, with ORF3 (gene 3) encoding a protein of unknown function.
(B) The NL63 genome was divided into five cDNA fragments (desig-
nated NL63-A to NL63-E) flanked by unique type IIS restriction
endonuclease sites that enable a seamless, unidirectional assembly of
the entire genome. Fragment NL63-A contains a T7 promoter se-
quence and NL63-E a poly(A) tail [A(n)]. In addition, ORF3 was
deleted and a heterologous gfp gene inserted in its place in the NL63-E
fragment to form fragment NL63-Egfp, which was used to engineer an
NL63 clone with GFP as a marker of infection.
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the marker mutation (NL63-73002 [ATAAGATTCAGGATGTTG] and
NL63-7R [GCAACAACCACAACAACCTG]) (Table 1) were used to amplify
this region of the genome of wt NL63, recombinant icNL63, and recombinant
icNL63gfp by RT-PCR. In all cases, an 1,000-bp PCR product was detected by
electroporation on a 0.8% agarose gel, and the band for each virus was excised
and gel purified by using a Qiaex II gel extraction kit (Qiagen) with modifications
(67) as described above. Analysis of the genotype was conducted by restriction
digestion of the 1,000-bp DNA with the BstAPI restriction endonuclease. Briefly,
25 l of DNA for each virus was incubated with 1 l BstAPI, 3 l NEB (New
England Biolabs) buffer 3, and 1 l double-distilled water at 60°C for 2 h and
then electroporated on a 0.8% agarose gel. The remaining 5 l of DNA was used
to sequence the fragment for genotype verification.
Growth kinetics and RNA analysis. For the growth curve analysis, LLC-MK2
cells were inoculated at a multiplicity of infection (MOI) of 0.003 PFU/cell in
12-well plates with a 1-h adsorption period, followed by three washes with PBS.
Two milliliters of medium was added to each culture, and the infections main-
tained at 32°C. The supernatants were harvested, at 300 l per time point with
300 l of medium added back, at 0, 8, 24, 48, 72, 96, 120, 144, 168, and 192 h
postinoculation (p.i.). The titer for each virus at each time point was determined
by plaque titration in LLC-MK2 cells maintained at 32°C, as described above.
For Northern blot analysis, total RNA was harvested in Trizol reagent (Invitro-
gen), following the manufacturer’s protocol, from cells infected at an MOI of
0.003 PFU/ml and harvested at 96 h p.i. The total RNA was diluted, and 5 g was
used for each virus, including wt NL63, recombinant icNL63, and recombinant
icNL63gfp. The RNA from each infection was separated by gel electrophoresis,
transferred to a nitrocellulose membrane, and probed with a 31-nt cDNA probe
(3-CTCTTGAACATTCCAATAACCAATCTGCTCT-5; N gene positions 151
to 180, italicized residues were biotinylated) designed to detect genomic and
subgenomic RNAs by using a NorthernMax-Gly system (Ambion) following a
modified protocol. Briefly, the exact procedure was followed up to and including
the overnight 42°C hybridization of the probe to RNA cross-linked to the mem-
brane. The next morning, the membrane was washed one time in low-stringency
wash solution for 10 min, followed by a second wash in low-stringency wash
solution at 45°C for 2 min. A third and final wash was conducted for 2 min at
45°C in a 50/50 mixture of high-stringency and low-stringency wash solutions.
Detection of bands was accomplished by using a BrightStar BioDetect system
(Ambion) following the manufacturer’s protocol. The membrane was then ex-
posed to film, which was prepared for publication by using Adobe Photoshop CS.
IFA. LLC-MK2 cells were grown to 70 to 80% confluence on four-well cham-
ber slides (Lab-Tek, NUNC) and inoculated with recombinant icNL63 at an
MOI of 1 PFU/cell or mock inoculated (medium alone). At 48 h p.i., the
medium was aspirated, and the cells were fixed and permeabilized in 20°C
methanol overnight. The cells were rehydrated in PBS for 30 min and blocked in
buffer comprised of PBS with 5% bovine serum albumin. All subsequent immu-
nofluorescence assay (IFA) steps were conducted at 25°C in IFA assay wash
buffer comprised of PBS containing 1% bovine serum albumin and 0.05% Non-
idet P-40. After being blocked, the cells were incubated in the primary antibody,
anti-N (anti-NL63 N; generously provided by Lia van der Hoek), diluted 1:1,000,
for 1 h. The cells were then washed in IFA assay wash buffer three times at 10
min/wash. Next, the cells were incubated in the secondary antibody (goat anti-
rabbit Alexa 488, diluted 1:1,000; Molecular Probes) for 45 min. Next, the cells
were washed three times at 10 min/wash, followed by a final wash of 30 min in
PBS. The cells were then visualized by fluorescent microscopy. The images were
prepared for publication by using Adobe Photoshop CS.
Western blotting. LLC-MK2 cells were mock inoculated (medium alone) or
inoculated with wt NL63, recombinant icNL63, or recombinant icNL63gfp at an
MOI of 0.003, and at 144 h p.i., cells were washed in 1 PBS, lysed in buffer
containing 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.5% deoxycholine, 1%
Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS) and postnuclear supernatants
were added to an equal volume of 5 mM EDTA–0.9% SDS, resulting in a final
SDS concentration of 0.5%. Equivalent sample volumes were loaded onto 4 to
20% Criterion gradient gels (Bio-Rad) and transferred to polyvinylidene diflu-
oride membranes (Bio-Rad). The blots were probed with polyclonal rabbit an-
tisera directed against the NL63 N protein (kindly provided by Lia van der Hoek)
diluted 1:1,000 or with antisera directed against GFP (Clontech) diluted 1:1,000
and developed using chemiluminescence reagents (Amersham Biosciences).
Inoculation of HAE cultures. Prior to apical inoculation, the apical surfaces of
HAE were rinsed three times over 30 min with PBS at 37°C, and inoculations
were performed at 32°C with 200 l of recombinant icNL63 or recombinant
icNL63gfp virus stock (104 PFU/ml). Following a 2-h incubation at 32°C, the
inoculant was removed, and HAE was maintained at 32°C for the remainder of
the experiment. To generate growth curves at specific times after viral inocula-
tion, 120 l of tissue culture medium was applied to the apical surface of HAE
and collected after a 10-min incubation at 32°C. All samples were stored at
80°C until assayed for plaque formation on LLC-MK2 cells.
RESULTS
Design and assembly of icNL63 and icNL63gfp. A full-length
consensus sequence for NL63 was not possible, as all of the
full-length sequences available at the National Center for Bio-
technology Information (NCBI) differed significantly (see Fig.
S1 in the supplemental material). Therefore, we sequenced the
virus from an efficiently replicating stock and built the cDNA
clone based upon this sequence (FJ211861). For icNL63, the
NL63 genome was divided into five cDNA fragments (NL63-A
through NL63-E) with unique type IIS endonuclease restric-
tion sites flanking each junction (Fig. 1). For icNL63gfp, the
same strategy was used, although the heterologous GFP gene
was inserted in place of and under the control of the same
transcriptional regulatory sequence as the accessory ORF3 in
NL63-E, and this construct was designated NL63-Egfp (Fig. 1).
To assemble the clones, the fragments were cut by restriction
digestion (BsmBI and/or BstAPI) to remove the nonnative
portion of the restriction site and sequence, leaving unique,
asymmetrical sticky ends. The digested fragments were then
ligated to generate the full-length cDNA clones, with NL63-
Egfp being used instead of NL63-E for icNL63gfp (Fig. 1). A
T7 promoter site engineered at the 5 end of the genome in
fragment NL63-A was used to drive in vitro transcription of the
full-length cDNA to infectious RNA (Fig. 1). LLC-MK2 cells
were transfected with the full-length RNA for each clone, and
the cells monitored for CPE.
Detection of recombinant icNL63 and recombinant icNL63gfp
replication. To determine if replication occurred in the icNL63
transfection cultures, cells were examined at regular intervals
for CPE, which in LLC-MK2 cells is discernible as rounded
cells that appear on top of the monolayer. In the case of
recombinant icNL63, CPE was not conclusive at any time, but
recovery of recombinant icNL63 was detected in passage 3 by
RT-PCR amplification of leader-containing transcripts and
further verified by an IFA with anti-N antibody and by plaque
titration (Fig. 2A to D).
For recombinant icNL63gfp, replication was confirmed by
observing GFP fluorescence following transfection or inocula-
tion (Fig. 3). While fluorescent foci were observed as early as
2 days posttransfection at 32°C, additional passages at 7-day
intervals were necessary to infect most of the cells in the
culture. By 7 days p.i. of passage 3, there was obvious CPE in
the recombinant icNL63gfp-infected cells (Fig. 3A). Cells and
supernatants were harvested when nearly 100% of cells showed
strong evidence of GFP fluorescence. Replication and the
presence of viral subgenomic mRNA encoding viral structural
proteins or GFP were further verified by RT-PCR (data not
shown).
Plaque purification and titration of rescued virus. Viruses
rescued from the icNL63 and icNL63gfp transfections were
plaque purified, and stocks were propagated on LLC-MK2
cells. For recombinant icNL63, plaques were round and clear
with an approximate diameter of 2.5 to 3 mm (Fig. 2). For
recombinant icNL63gfp, plaques were clearly visible by fluo-
rescent microscopy (Fig. 3D) and similar to recombinant
icNL63, with the main difference observed between recombi-
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nant icNL63 and recombinant icNL63gfp plaques being one of
definition, as the recombinant icNL63 plaques were clearly
visible, while the recombinant icNL63gfp virus formed fuzzy
plaques that were slightly smaller. Interestingly, all plaques for
recombinant icNL63gfp were fluorescent. The viral titers de-
rived from recombinant icNL63 plaques reached 2  104
PFU/ml in LLC-MK2 cells, while the titers for recombinant
icNL63gfp were slightly higher, reaching a titer of 8  104
PFU/ml. The recombinant icNL63 virus titers were consistent
with the peak virus titers reported previously for wt NL63 virus
(2  105 PFU/ml) (46, 47, 59).
Detection of marker mutations in the rescued viruses. As
part of the cloning strategy, a silent BstAPI restriction endo-
nuclease site was engineered into both the icNL63 and
icNL63gfp clones at the NL63-D and NL63-E or NL63-Egfp
junction to facilitate the unidirectional ligation of the NL63-D
and NL63-E fragments. To verify that each clone had this
marker mutation, viral RNA was harvested from cultures in-
fected with plaque-purified stocks, and the 1,000-nt region
flanking the BstAPI site was amplified by RT-PCR (Fig. 4). In
all cases, an 1,000-nt PCR product was present following
electroporation, and the band for each virus was excised and
gel purified (Fig. 4). The purified 1,000-nt DNA from each
virus was then digested with the BstAPI restriction endonucle-
ase. Viral cDNA harvested from icNL63 and icNL63gfp re-
combinant viruses was digested into two bands of 600 nt and
400 nt, respectively (Fig. 4), while the wt NL63 viral cDNA was
not cleaved by this enzyme (Fig. 4). Further, this region was
sequenced to verify that the marker mutation was present in
the two clones, and this was the case for both recombinant
viruses (Fig. 4).
Growth kinetics and RNA analysis. To determine if the
recombinant viruses rescued from the two clones generated
similar quantities of viral mRNAs, Northern blot analysis was
performed (Fig. 5A). The results of this analysis demonstrated
that while recombinant icNL63gfp did not generate amounts of
viral mRNAs equivalent to those generated by wt NL63, it did
contain a unique, appropriately sized mRNA indicative of GFP
(Fig. 5A). To determine if the recombinant viruses generated
from the two clones grew with growth kinetics similar to those
of wt NL63, a growth curve analysis was conducted. In general,
viral growth was similar for wt NL63 and both recombinant
viruses, although recombinant icNL63 appeared to have a
shorter lag phase than wt NL63 and recombinant icNL63gfp
(Fig. 6).
Analysis of recombinant viruses by Western blotting. A
Western blot analysis was conducted to compare the levels of
viral protein expression of wt NL63, recombinant icNL63, and
recombinant icNL63gfp by using antisera against NL63 N and
GFP. While all three viruses generated detectable levels of N
protein, there was an obvious reduction in the recombinant
icNL63gfp lane, suggesting that this virus does not produce wt
levels of viral proteins (Fig. 5C); only recombinant icNL63gfp
expressed the 28-kDa GFP protein (Fig. 5B). These results are
consistent with those of Northern blotting, which demon-
strated that recombinant icNL63gfp is also deficient in RNA
synthesis but generates a subgenomic RNA consistent with the
GFP gene engineered into the clone (Fig. 5A). The recombi-
nant icNL63 virus mimics wt NL63 in RNA synthesis and
protein expression (Fig. 5A to C).
FIG. 3. Detection of replication in LLC-MK2 cells infected with
icNL63gfp. (A) CPE was evident in cells transfected with icNL63gfp
after passage 3, as indicated by rounded clumps of cells that grew on
top of the monolayer, forming long continuous striations. (B) GFP
fluorescence was detected as early as 24 h p.i.; however, the spread of
GFP fluorescence to nearly every cell required three passages.
(C) Cells infected with wt NL63 virus generated no detectable fluo-
rescence beyond the normal background level. (D) Cells infected with
recombinant icNL63gfp and covered with overlay medium formed
plaques distinguished by fluorescent foci within the monolayer.
FIG. 2. Detection of replication in cells inoculated with icNL63
passage 3 supernatants. (A) Supernatants from the icNL63 transfec-
tion flask were used to inoculate four-well chamber slides of LLC-MK2
cells to assay for the presence of NL63 N protein by IFA. Nucleocapsid
protein was detected in these cells, and it exhibited a perinuclear
localization pattern. (B) In mock-infected cells, N protein was not
detected. (C) While CPE was not dramatic, the supernatants from the
icNL63 transfection resulted in various sizes of plaques. (D) Sub-
genomic transcription was verified by real-time RT-PCR by assaying
for leader-containing transcripts. Amplification of the viral cDNA for
wt NL63 (f) and recombinant icNL63 (Œ) occurred at nearly identical
cycle thresholds, suggesting that recombinant icNL63 generated quan-
tities of subgenomic N gene that were similar to the quantities gener-
ated by wt NL63. LLC-MK2 cells (●) and the control without template
() showed no amplification.
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Recombinant NL63 infections in HAE cultures. A primary
target for infection by other hCoVs, like SARS-CoV and
hCoV-229E, is ciliated cells (51) of the upper airways. As
ciliated cells express robust levels of ACE2 (20), we next de-
termined if the recombinant icNL63 and icNL63gfp viruses
could replicate efficiently in these cultures of HAE. The infec-
tion of HAE by recombinant icNL63gfp was detected as fluo-
rescent cells on day 1 (24 h p.i.), and the fluorescence increased
in intensity at each time point of the experiment (Fig. 7),
although its spread to additional cells appeared to be limited
(Fig. 7). In HAE, recombinant icNL63 CPE was not evident,
although virus was isolated and determined to reach peak titers
of 5  104 on day 4 (96 h p.i.). In contrast, recombinant
icNL63gfp achieved peak titers of 7.5  103 on day 5 (120 h
p.i.) (Fig. 7).
These results indicate that recombinant NL63 viruses de-
rived from the cDNA clones replicated as efficiently as biolog-
ically derived NL63 and grew in LLC-MK2 cells and HAE and
that the replacement of ORF3 with the gfp transgene allowed
the expression of GFP in infected cells. While ORF3 appears
to be nonessential in cell culture, there were differences in
RNA synthesis, protein expression, plaque morphology, and
growth in HAE that suggest that ORF3 may play an important
undetermined role during in vivo infection.
DISCUSSION
A reverse genetics system for NL63 provides a platform for
studying this virus in depth and is a necessary component in the
development of vaccine candidates, vaccine vectors, and ther-
apeutics. In this study, we developed a reverse genetics system
for NL63 and rescued recombinant NL63 viruses by utilizing
the same cloning strategy employed to generated infectious
clones of TGEV (65), MHV (67), IBV (7), and SARS-CoV
(66). In general, plaque-purified wt NL63 and recombinant
icNL63 viruses were indistinguishable in cell culture, as both
generated nearly round plaques of 2.5 to 3 mm in diameter in
LLC-MK2 cells (Fig. 2), exhibited similar levels of RNA syn-
thesis and protein expression (Fig. 5), and replicated with
similar growth kinetics (Fig. 6). Interestingly, although recom-
binant icNL63 appeared to have a shortened lag phase, this
difference fell within the range of error for the experiment and
FIG. 4. Verification of the marker mutation in rescued virus from
icNL63 and icNL63gfp. A silent BstAPI site introduced into both
clones at the NL63-D and NL63-E or NL63-Egfp junctions was used to
verify that the viruses rescued from the transfection flasks were gen-
erated from the cloned cDNA. (A) A 1,000-nt region flanking this site
was amplified by PCR, digested by BstAPI, and analyzed by gel elec-
trophoresis. Lane 1, marker; lane 2, wt NL63 was not cut by BstAPI;
lane 3, the DNA from this region in the icNL63 recombinant virus was
cleaved by BstAPI; and lane 4, the DNA from this region in the
icNL63gfp recombinant virus was also cleaved by BstAPI. To verify the
genotype, this region was sequenced for icNL63, icNL63gfp and wt
NL63. Molecular sizes in nucleotides are shown on the left. (B) The
chromatograms of icNL63 and icNL63gfp were identical in this region
and are shown here. (C) The sequence chromatogram of wt NL63 in
this region. The differences between the two chromatograms are indi-
cated by the boxes. The BstAPI recognition site is GCANNNNNTGC.
FIG. 5. Verification of replication by Northern and Western blotting. (A) A Northern blot analysis was conducted using viral RNA harvested from
LLC-MK2 cells infected with wt NL63, recombinant icNL63, or recombinant icNL63gfp. Six bands were detected which correspond to the six viral genes.
The protein product that arises from each gene is indicated in parentheses. The recombinant icNL63gfp virus produced an mRNA band that corresponds
to the GFP transgene and lacked the mRNA corresponding to gene 3 (ORF3), whereas wt NL63 and recombinant icNL63 viruses produced the six
expected viral RNAs. (B) A Western blot was conducted using the anti-GFP antibody to detect the GFP protein from infected-cell lysates, which was
only detectable for the recombinant icNL63gfp virus. (C) A Western blot was conducted using the anti-N antibody to detect the N protein. N protein
expression was reduced for the recombinant icNL63gfp virus. Molecular masses in kilodaltons are shown between the blots.
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was likely due to differences in cell culture and not differences
in the recombinant icNL63 virus (Fig. 6). In addition, recom-
binant icNL63 viral RNA contained the unique marker intro-
duced into the clone sequence to allow verification that the
virus was derived from the engineered clone (Fig. 4). To test
the utility of this reverse genetics system, we removed the
accessory ORF3 from the NL63 genome and replaced it with
the gene for GFP, creating a unique system for monitoring
NL63 infection in real time. In addition, the results of this
experiment demonstrated that the ORF3 protein is nonessen-
tial for the replication of NL63 in LLC-MK2 cells. This obser-
vation was in agreement with the results of several other stud-
ies which have shown that CoV accessory and luxury ORFs are
dispensable for in vitro replication (17, 66, 68).
The replacement of ORF3 with the heterologous GFP gene
resulted in infected cells that were detectable by fluorescent
microscopy (Fig. 3), and the recombinant icNL63gfp virus gen-
erated titers and exhibited growth kinetics that were essentially
identical to those of wt NL63 and recombinant icNL63 in
LLC-MK2 cells (Fig. 6). Interestingly, recombinant icNL63gfp
virus generated plaques that were slightly smaller (2 to 2.5 mm
in diameter versus 2.5 to 3 mm), with irregular borders, and
were considerably less-well defined than wt NL63 plaques
(data not shown). Although the different plaque phenotype did
not correlate to a reduction in growth kinetics (Fig. 6), recom-
binant icNL63gfp had modestly reduced levels of RNA syn-
thesis (Fig. 5A) and protein expression (Fig. 5C) compared to
those of wt NL63. The lack of an animal model for studying
NL63 made it impossible to determine if ORF3 plays a role in
viral pathogenesis in vivo.
At the time of this study, 12 NL63 genomes containing a
full-length ORF3 sequence were available at NCBI, and
among these, ORF3 was strictly (100%) conserved at the
amino acid level in all isolates, while most ORF3 genes varied
1 to 2% at the nucleotide level. While this suggests an impor-
tant role for the ORF3 protein product in vivo, ORF3 deletion
from icNL63gfp was not deleterious to replication in LLC-
MK2 cells. This finding was not surprising given that the dis-
tantly homologous proteins ORF4 in hCoV-229E (12) and
ORF3a in SARS-CoV (17, 68) have also been shown to be
nonessential in cell culture. Group-specific ORFs of several
different CoVs have been deleted, and while some deletions
attenuated pathogenesis or viral growth in vitro, the function
of most is unknown. Two exceptions are the ORF3b and ORF6
products of SARS-CoV, which have been characterized as
interferon antagonists (16, 29). Whether ORF3 of NL63 en-
codes interferon antagonist activities remains to be deter-
mined. In preliminary studies, we have observed that GFP-
tagged ORF3 protein localizes to the nucleus when transfected
into cells (data not shown).
In addition to the transfection of LLC-MK2 cells, recombi-
nant icNL63 and recombinant icNL63gfp were used to infect
primary HAE, which supports the infection and spread of
other respiratory pathogens, such as influenza virus, respira-
tory syncytial virus (RSV), SARS-CoV, and paramyxoviruses
(4, 49–51, 56, 69). Since NL63 infects both the upper and lower
respiratory tracts and HAE cultures maintain the form and
function of human ciliated airways, these cultures represent a
relevant and authentic model for studying this virus. Not sur-
FIG. 6. Growth kinetics of wt NL63 and recombinant icNL63 and
icNL63gfp viruses. All three viruses grew with similar growth kinetics,
although recombinant icNL63 virus () appeared to have a shorter lag
phase. The growth kinetics of wt NL63 (●) and recombinant
icNL63gfp (Œ) were nearly identical at every time point until day 7
(168 h p.i.), when wt NL63 reached peak titers of 5  105 PFU/ml.
Recombinant icNL63 reached a peak titer of 3  105 on day 6 (144 h
p.i.), and recombinant icNL63gfp reached a titer of 1.5  105 PFU/ml
on the same day. All virus titers at each time point fall within 1
standard deviation, suggesting that all titers are similar.
FIG. 7. Time course of infection of HAE and viral titers produced
by recombinant icNL63 and icNL63gfp. HAE cultures were inoculated
with recombinant icNL63 and recombinant icNL63gfp and monitored
for 6 days. Fluorescence was detected in HAE infected with recombi-
nant icNL63gfp by 24 h p.i. and continued to be detected throughout
the course of the experiment. (A to E) Images showing the recombi-
nant icNL63gfp-infected HAE at 24-h intervals beginning with the
24-h p.i. time point and continuing through 120 h p.i. (F) SARS-CoV-
GFP-infected HAE cultures at 120 h p.i. produced smaller fluorescent
foci. (G) Titers were determined for both recombinant icNL63 (black)
and recombinant icNL63gfp (hatched) at each time point.
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prisingly, both recombinant viruses grew in HAE (Fig. 7G),
and recombinant icNL63gfp was detectable by fluorescence by
24 h p.i. with increased fluorescent intensity over time, al-
though its spread from cell to cell was somewhat limited (Fig.
7A to E). In contrast, SARS-CoV expressing GFP in an acces-
sory ORF was used to infect HAE cultures, and spreading of
this virus was evident over the course of the infection (Fig.
7G). Spreading of RSV in HAE has also been observed (70).
Interestingly, the fluorescent foci detected with recombinant
icNL63gfp infection were smaller and generally more diffuse
than those observed in HAE infected with the recombinant
SARS-CoV expressing GFP (Fig. 7F) (50). Although this may
be due to variability between cultures, we cannot rule out the
possibility that ORF3 is nonessential for replication in LLC-
MK2 cells but may play a role in more-relevant tissues that are
related to replication in nonimmortalized cell lines. The results
of previous studies have shown that parainfluenza virus and
RSV infection of HAE mimic their in vivo replication capac-
ities, while in cell lines, attenuation is not seen (69, 70). We
speculate that ORF3 might be required for efficient viral egress
in HAE, as spreading within cultures was reduced in the re-
combinant icNL63gfp virus. This is supported by the fact that
recombinant icNL63gfp appeared to grow less efficiently than
recombinant icNL63 in HAE (Fig. 7G).
Engineering GFP into icNL63 and rescuing recombinant
viruses expressing this marker protein provides an important
reagent enabling the testing of drugs and therapeutic agents
against infections in real time. Several other viral systems have
utilized a similar approach to generate novel reagents which
allow high-throughput therapeutic screening (3, 15, 19, 22, 31,
33, 35, 38, 54, 58). In LLC-MK2 cells, we observed viral spread
throughout the culture, even though there were no detectable
differences in CPE. While only a few fluorescent foci were
present at early times posttransfection, over time we observed
more and more fluorescence spreading to neighboring cells.
Fluorescence was also detectable in the HAE, providing a
platform to monitor the infection of primary HAE in real time.
Importantly, in all cases the GFP transgene was highly stable in
the NL63 genome for over 2 months in culture, an important
feature for the development of hCoV vaccine vectors.
All hCoVs, with the exception of SARS-CoV, grow poorly in
cell culture, while some, including hCoV-OC43 and hCoV-
229E, do not generate plaques, making downstream assays
difficult to perform. Moreover, a new hCoV associated with
pneumonia in adults, known as HKU-1, has never been suc-
cessfully cultured in vitro. Poor growth in culture makes it
extremely difficult to rescue recombinant viruses from full-
length cDNA clones, which makes manipulating these virus
genomes difficult. NL63 has an intermediate growth phenotype
in cell culture, where it grows at an optimal temperature of
32°C, requiring 7 days to reach peak titer in LLC-MK2 cells,
while SARS-CoV grows at 37°C with a distinct growth advan-
tage, allowing it to reach peak titers in 48 h p.i. in Vero cells.
These observations indicate that more-robust culture systems
are needed for the development of NL63 as a vaccine vector
for human use.
There are several distinct features that suggest that NL63
would be an efficacious vaccine vector, and these include (i)
natural targeting of respiratory pathogen antigens to the ap-
propriate mucosal epithelial cells lining the upper airways for
optimal mucosal immune induction; (ii) virus induction of ro-
bust humoral, mucosal, and possibly cellular immune respons-
es; and (iii) a genome size, organization, and helical nucleo-
capsid assembly scheme that allow (a) coordinated gene
expression; (b) the deletion of luxury genes that are nonessen-
tial for replication; and (c) stable incorporation of multiple,
large gene inserts (17, 66, 68). As a proof of principle, in this
report we demonstrated that replacing the luxury ORF3 with
heterologous gfp allowed stable targeting of GFP to the cells
infected by NL63. Hypothetically, multiple heterologous anti-
gens with novel transcriptional regulatory sequences could be
engineered into the intergenic space between a propagation-
deficient set of structural genes, providing a multivalent, rep-
lication-competent, propagation-deficient virus vector vaccine
approach capable of immunizing against multiple viruses si-
multaneously. The complementation of such a vector in cells
expressing the propagation-deficient gene could be utilized to
assemble viable viruses that would act as one-hit vectors, gen-
erating antigen at the targeted cell while lacking the necessary
components to generate a viable viral particle. A similar strat-
egy was reported for TGEV whereby the E gene was expressed
in a replicon cell system, which allowed the TGEV vaccine
vector to be packaged as a viable virus and grown to high-titer
replicon stocks (40). An NL63-based vaccine vector would
potentially replicate extensively in the upper and, to a lesser
extent, lower respiratory tract by targeting cell populations on
mucosal surfaces that express ACE2, such as HAE, lung alve-
olar epithelial cells, and oral and nasal mucosa (21).
A current impediment in the field is the lack of either a small
or large animal model of NL63 replication or pathogenesis.
While mice express an ACE2 variant, virus replication has not
been detected in mice infected with NL63. Moreover, the
SARS-CoV receptor binding domain required adaptations in
the spike protein to accommodate the structural differences
imposed by the variations between the human and mouse
ACE2 molecules (48). Since NL63 utilizes a different receptor
binding domain and a different set of interactions, there may
be even more changes necessary to adapt NL63 to replicate in
mice. In addition, more-robust cell culture systems will be
required for the propagation of NL63 as a vaccine vector
system. In general, icNL63 makes a powerful vaccine platform,
as CPE can be detected in LLC-MK2 cells; it may use the same
receptor as has been described for SARS-CoV, a homologue
of which is present in mice, and the stable expression of GFP
will allow real-time monitoring of infections. These character-
istics are in contrast to the hCoV-229E clone, which grows
poorly and is difficult to detect by CPE (55).
The infectious clones described in this report provide a re-
verse genetics platform that can be used to develop candidate
vaccine strains that might one day reduce the impact of NL63
as an important respiratory pathogen that infects children and
adults worldwide. The benefits of such a vaccine would be to
reduce the overall disease burden in children and perhaps
reduce cases of croup. The availability of icNL63 and
icNL63gfp provides research opportunities which will advance
our understanding of in vivo tropisms and assist in the devel-
opment of small and large animal models of infection. More-
over, detailed genetic manipulation of the genome will assist in
understanding the role of viral genes in replication and patho-
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genesis and lead to the development of hCoV-based vectored
vaccines.
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